Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
PALO ALTO, Calif.--(BUSINESS WIRE)-- #LILRB4--Fast Track designation for IO-202, a myeloid checkpoint inhibitor antibody targeting LILRB4 (ILT3), for the treatment of r/r acute myeloid leukemia
